Coherus Oncology (CHRS) Return on Invested Capital (2021 - 2023)
Coherus Oncology (CHRS) reported Return on Invested Capital of 0.36% for Q4 2023, down 244.74% sequentially from 0.1% in Q3 2021.
Coherus Oncology (CHRS) Return on Invested Capital (2021 - 2023) Analysis & Trends
Coherus Oncology (CHRS) has 2 years of Return on Invested Capital data on file, last reported at 0.36% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -0.36% |
| Sep 30, 2021 | -0.10% |